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Peroxisome proliferator-activated receptor b (PPARb) is a member of the nuclear hormone receptor family and is a ligand-activated
transcription factor with few known molecular targets including 3-phosphoinositide-dependent protein kinase 1(PDK1). In view of the
association of PPARb and PDK1 with cancer, we have examined the expression of PPARb and PDK1 in normal ovaries and different
histological grades of ovarian tumours. Normal ovaries, benign, borderline, grades 1, 2 and 3 ovarian tumours of serous, muciuous,
endometrioid, clear cell and mixed subtypes were analysed by immunohistochemistry for PPARb and PDK1 expression. All normal
ovarian tissues, benign, borderline and grade 1 tumours showed PPARb staining localised in the epithelium and stroma. Staining was
predominantly nuclear, but some degree of cytoplasmic staining was also evident. Approximately 20% of grades 2 and 3 tumours
lacked PPARb staining, whereas the rest displayed some degree of nuclear and cytoplasmic staining of the scattered epithelium and
stroma. The extent of epithelial and stromal PPARb staining was significantly different among the normal and the histological grades of
tumours (w
2¼59.25, d.f.¼25, Po0.001; w
2¼64.48, d.f.¼25, Po0.001). Significantly different staining of PPARb was observed in
the epithelium and stroma of benign and borderline tumours compared with grades 1, 2 and 3 tumours (w
2¼11.28, d.f.¼4, Po0.05;
w
2¼16.15, d.f.¼4, Po0.005). In contrast, PDK1 immunostaining was absent in 9 out of 10 normal ovaries. Weak staining for PDK1
was observed in one normal ovary and 40% of benign ovarian tumours. All borderline and malignant ovarian tumours showed
positive cytoplasmic and membrane PDK1 staining. Staining of PDK1 was confined to the epithelium and the blood vessels, and no
apparent staining of the stroma was evident. Significantly different PDK1 staining was observed between the benign/borderline and
malignant ovarian tumours (w
2¼22.45, d.f.¼5, Po0.001). In some borderline and high-grade tumours, staining of the reactive
stroma was also evident. Our results suggest that unlike the colon, the endometrial, head and neck carcinomas, overexpression of
PPARb does not occur in ovarian tumours. However, overexpression of PDK1 was evident in borderline and low- to high-grade
ovarian tumours and is consistent with its known role in tumorigenesis.
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Peroxisome proliferator-activated receptors (PPARs) are members
of the nuclear receptor superfamily (Feige et al, 2006). The three
closely related PPAR isoforms identified as PPARa (NR1C1),
PPARb (NR1C2) and PPARg (NR1C3) are encoded by separate
genes and fulfil specific functions (Michalik et al, 2003). As
transcription factors requiring activation, the PPARs modulate the
expression of target genes in the cytoplasm or in the nucleus in
response to ligand binding. Physiological ligands of PPARs include
fatty acids and their derivatives, leukotrienes and prostaglandins.
DNA binding by PPAR requires heterodimerisation with the
retinoid X receptor (RXR), the receptor for 9-cis retinoic acid. The
PPAR-RXR heterodimer binds to the promoter region of its target
genes on a specific DNA sequence element, termed the peroxisome
proliferators-responsive element (Nahle, 2004), and upon ligand-
dependent activation stimulates the transcription of genes by
recruiting co-activators.
Peroxisome proliferator-activated receptor b is ubiquitously
expressed and has been implicated in adipose tissue formation
(Bastie et al, 2000), brain development (Peters et al, 2000),
placental function (Barak et al, 2002), wound healing (Di-Poi et al,
2003) and atherosclerosis (Planavila et al, 2005). The antiapoptotic
role of PPARb contributes to efficient wound healing in the skin
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sand is mediated by the transcriptional upregulation of integrin-
linked kinase (ILK) and PDK1 (Di-Poi et al, 2002). The role of
PPARb has been controversial in the field of cancer. In colon
cancer, PPARb expression was shown to be associated with
intestinal tumorigenesis, with increased mRNA levels being
observed in several colorectal cancer cell lines and colon tumours
(Park et al, 2001a; Burdick et al, 2006). A PPARb-deficient colon
cancer cell line was defective in establishing tumours when grown
as xenografts in nude mice (Park et al, 2001a), and the activation
of PPARb by a synthetic ligand in mice pre-disposed to intestinal
tumorigenesis (Apc
Min mice) resulted in a significant increase in
the number and size of intestinal polyps (Gupta et al, 2004).
Heightened expression of PPARb has also been demonstrated in
head and neck carcinomas (Jaeckel et al, 2001) and endometrial
carcinomas (Tong et al, 2000). Peroxisome proliferator-activated
receptor b agonist has been shown to act as a tumour promoter in
a mammary carcinogenesis model (Yin et al, 2005) and to
proliferate the growth of human hepatocarcinoma cell line HepG2
(Glinghammar et al, 2003). Contrary to these reports, however, the
presence of PPARb expression has also been shown to decrease
during colon carcinogenesis in both the Min mutant and
chemically induced mouse models, where colon polyp formation
was significantly greater in mice null for PPARb expression
(Harman et al, 2004). Consistent with that, others have recently
demonstrated APC
Min PPARb null mice to have an increased
predisposition to intestinal tumorigenesis (Reed et al, 2004). In the
same way, the ligand activation of PPARb in PPARb
þ/þ mice
resulted in increased expression of colonocyte differentiation and
apoptosis, inhibition of colon polyp multiplicity, effects not
observed in PPARb
 /  mice (Marin et al, 2006). In addition,
PPARb-dependent regulation of ubiquitin has been shown to
attenuate skin carcinogenesis (Kim et al, 2004). These reports
suggest the growth inhibitory and differentiation role of PPARb in
colon and skin carcinogenesis and contradict the growth-promo-
ting reports described previously.
The function of activated PPARb is dependent on the activities
of its putative downstream targets PDK1 and ILK, both of which
act as oncogenes when expressed in mammary epithelial cells
(Somasiri et al, 2001; Zeng et al, 2002), and are involved in the
activation of cell proliferation and survival pathways. Peroxisome
proliferator-activated receptor b-mediated activation of ILK and
PDK1 is controlled at the transcriptional level (Di-Poi et al, 2002,
2005; Tan et al, 2003) and is closely connected to the decrease of
PTEN expression (Han et al, 2005), commonly lost in tumours,
including those of ovarian origin (Dinulescu et al, 2005). This
activation cascade triggers the Akt1 survival pathway normally
seen in the activation of growth factor receptors or integrin-linked
signals (Ahmed et al, 2005). We have recently demonstrated
increased ILK expression in high-grade ovarian tumours and
epithelial ovarian cancer cell lines (Ahmed et al, 2003). Moreover,
Akt, the most extensively studied downstream target of both ILK
and PDK1, has also been shown to be overexpressed in ovarian
carcinomas (Arboleda et al, 2003). Recently, it has been
demonstrated that targeting PDK1 by antisense oligonucleotides
blocks the proliferation of U-87 glioblastoma cells by promoting
apoptosis (Flynn et al, 2000b). Consistent with that, the expression
of PDK1 in mouse mammary epithelial cells has been shown to
drive neoplastic transformation through the activation of Akt1 and
PKCa pathways (Zeng et al, 2002). In addition, the expression of
PDK1 in mammary cancer cells was shown to modulate MMP-2
activation with concomitant modulation of ECM proteins decorin
and collagen (Xie et al, 2006). These data suggest that abnormal
expression and activation of PDK1 initiate neoplastic transforma-
tion and provide a framework for the cells towards a tumorigenic
phenotype.
In addition to PPARb activation, the aberrant activation of
growth factor receptors and their downstream target such as
activation of PI-3 kinase (Roymans and Slegers, 2001) also controls
PDK1 (Toker and Newton, 2000; Vanhaesebroeck and Alessi, 2000;
Fresno Vara et al, 2004). Many cancers including ovarian cancer,
possess elevated levels of PI-3 kinase (Miled et al, 2007). Cells
having increased PI-3 kinase activity possess mutated PTEN and
have elevated levels of PKB (Alessi et al, 1997) and PDK1 (Bayascas
et al, 2005) activity, which in turn activates several protein serine/
threonine kinases, including PKC (Dutil et al, 1998; Le Good
et al, 1998), ribosomal S6 kinase (Alessi et al, 1998), SGK
(Pullen et al, 1998), Rho kinase (Flynn et al, 2000a) and PAK1
(King et al, 2000), all of which are associated with increased
invasion and metastasis (Park et al, 2001b). Recently, it has been
demonstrated that reducing the expression of PKB in PTEN-
deficient cells reduces aggressive growth and promotes apoptosis
(Stiles et al, 2002), whereas reducing the expression of PDK1 in
heterozygous PTEN
þ/  mice markedly protects these animals from
developing a wide range of tumours (Bayascas et al, 2005). These
results suggest PDK1 as a key mediator of neoplasia and validate
PDK1 as a promising anticancer target for the prevention of
tumour formation.
In this study, we have examined the expression of PPARb and
PDK1 in normal ovaries, benign tumours and the histological
grades of ovarian tumours. We demonstrate that nuclear and
cytoplasmic PPARb is located in the epithelial and stromal cells of
normal ovaries, benign tumours and low- to high-grade ovarian
carcinomas. On the other hand, normal ovaries and a bulk of
benign ovarian tumours demonstrate no significant expression
of PDK1, but enhanced cytoplasmic and membrane expression of
PDK1 was observed in borderline and low- to high-grade ovarian
tumours. Our results suggest that PPARb may have a distinct role
in normal and malignant ovarian physiology, whereas PDK1 may
be associated with ovarian tumour progression and metastasis. To
our knowledge, this is the first study that describes a detailed
expression profile of PPARb and PDK1 in normal ovaries, benign
tumours and all histological grades of ovarian carcinomas.
MATERIALS AND METHODS
Antibodies and reagents
Rabbit polyclonal antibodies against PPARb and PDK1 were
obtained from Santa Cruz Biotechnology Inc. (sc-7197; Santa Cruz,
CA, USA) and Cell Signaling Technology (3062; Brisbane, QLD,
Australia).
Tissues
This study was approved by the Research and Human Ethics
Committee (HEC no. 02/30) of The Royal Women’s Hospital,
Melbourne, Australia. Ovarian cancer patients with serous,
mucinous, endometrioid, clear cell carcinoma and mixed subtypes
were included in the study. The histopathological diagnosis and
tumour grades were determined by two staff pathologists as part of
clinical diagnosis. Histological grading of ovarian carcinoma was
determined by the method described previously (Silverberg, 2000).
Normal ovaries were removed from patients undergoing surgery as
a result of suspicious ultrasound images, palpable abdominal
masses and/or family history after the provision of a participant
information statement and with informed consent. The histo-
pathological analysis of normal ovaries was evaluated by the staff
pathologists in the hospital.
Archival tissues were obtained from the Department of
Pathology, Royal Women’s Hospital, from women who presented
for surgery after the provision of a participant information
statement and with informed consent. With few exceptions, the
majority of the cases (B79%) evaluated for the immuno-
histochemical expression of PPARb and PDK1 were the same
(8 out of 10 in normal, 9 out of 10 in benign, 8 out of 9 in grade 1
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sand 8 out of 11 and 8 out of 11 in grades 2 and 3). A small
difference in the sampling (B21%) among normal and different
pathological grades of cancer was made where there was an
inadequate amount of specimens needed to complete both studies.
This was done with the purpose of having an adequate number of
samples for statistical analysis.
Description of patients included in the PPARb study
The mean age of healthy volunteers participating in the PPARb
study was 51 years, whereas that of women presenting with benign
and borderline tumours was 61 years. The mean age of women
with cancer was 60 years. Out of the 10 benign tumours, 8 were of
the serous subtype, whereas 2 were of the mucinous type. Eight out
of 10 borderline tumours were in the serous group, whereas 2 were
of the mucinous subtype. Seven out of nine grade 1 malignancies
used for the PPARb study were of endometrioid subtype, one was
mucinous and one of mixed subtype (endometrioid, mucinous,
serous). Seven of these patients had Stage 1 disease, whereas one
had Stage 2 and the other had Stage 3. Among grade 2 tumours,
eight had serous ovarian carcinoma, whereas two were of mixed
subtype (endometrioid, mucinous, clear cell carcinoma). All of
these patients except one (Stage 1) were of Stage 3. Eight out of 10
grade 3 tumours were of serous subtype, whereas one was
endometrioid and the other of clear cell subtype. Seven of these
grade 3 patients were Stage 3, one was Stage 2 and the remaining
two were Stage 4.
Description of women included in the PDK1 study
The mean age of the control group participating in the PDK1 study
was 51 years, whereas that of women presenting with benign and
borderline tumours was 70 years. The mean age of women with
cancer was 57 years. Eight out of 10 benign and borderline
tumours in each group were of the serous subtype, whereas two
were of the mucinous type. Six out of nine grade 1 tumours were of
endometrioid subtype, two were mucinous and one was of the
mixed subtype (endometrioid, mucinous, serous). Seven of these
patients had Stage 1 disease, whereas two were Stage 2. Among
grade 2 tumours, five were serous, two were mucinous, one
transitional and three of mixed subtype (endometrioid, mucinous,
clear cell carcinoma). Seven of these tumours were Stage 3 and
only four were Stage 1. Seven out of 11 grade 3 cancer patients
were of serous subtype, whereas two were endometrioid and the
other two of clear cell subtype. Seven of these grade 3 tumours
were Stage 3, one was Stage 2 and the remaining three were Stage 4.
Immunohistochemistry
Immunohistochemical analysis on ovarian tissues was performed
as described previously (Ahmed et al, 2002a,b). Briefly, paraffin
sections were cut at 4mm thickness, mounted on silane-coated
slides and incubated overnight at 371C. Sections were washed with
water after two changes of xylene and three changes of ethanol.
Antigen retrieval was performed using citrate buffer (pH 6.0) and
sections were held in Tris-buffered saline (TBS). Endogenous
peroxidase activity was removed using 3% hydrogen peroxide in
methanol. The sections were incubated for 1h in primary antibody
diluted 1:200 in 1% BSA in Tris buffer (100mM, pH 7.6). Antibody
binding was amplified using biotin and streptavidin HRP
(Chemicon, Temecula, CA, USA) for 15min each and the complex
visualised using diaminobenzidine (DAB). Nuclei were lightly
stained with Mayer’s haematoxylin. Non-immune rabbit serum
was used as a control. The specificity of PPARb and PDK1
antibodies was evaluated by Western blot in ovarian tumour
homogenates and ovarian cancer cell lysates. In both cases, right
molecular weight bands were observed.
Sections were assessed microscopically for positive DAB
staining. Two observers (NA and CR) independently evaluated
the immunostaining results, and the degree of staining was scored
in a blind manner. The concordance ratio was 495% in each case.
Differences in opinion were resolved by re-evaluating the sections
and, in some cases, by reaching a consensus with the assistance of
a third evaluator. Four sections were assessed per tissue, and the
cellular distribution of staining was determined.
Interpretation of staining results
Immunohistochemistry results were evaluated by two independent
observers using the following parameters:
(1) Staining pattern, that is, localisation of immunoreactive
PPARb and PDK1 in the cytoplasm, membrane and/or nucleus
of tumour epithelial and stromal cells;
(2) Presence and extent of staining using the following scale: for
each specimen, the positive staining extent was scored in 5
grades, namely 0 (p10%), 1 (X11–25%), 2 (X26–50%), 3
(X51–75%), 4 (X76–90%) and 5 (X 90–100%). The extent
of staining was further classified into three grades: negative
(0), low (1, 2), moderate (3) and high (4, 5).
Statistical analysis
The significance of the extent of immunohistochemical staining
between normal, benign, borderline and histological grades 1, 2
and 3 ovarian tumours was determined by the non-parametric
w
2 contingency test. Po0.05 was considered statistically
significant.
RESULTS
Immunohistochemical expression of PPARb in ovarian
tissues
Normal ovaries All normal ovarian sections examined showed
staining of PPARb on the surface epithelium (Figure 1A). In most
of the cases (7 out of 10), 50% of the epithelial nuclei were
positively stained. Extensive nuclear staining of the cortical stroma
was also evident. In some sections, contents of the inclusion cysts
and fallopian tubes also stained positively. Positive staining of the
macrophages was also evident in some sections.
Benign and borderline tumours Benign tumours exhibited
extensive epithelial staining with 6 out of 10 tumours exhibiting
450% of nuclear epithelial staining (Table 1, Figure 1B). The
associated stromal tissues also showed some degree of staining
confined to both nucleus and cytoplasm. Epithelial staining of the
inclusion cysts was also evident in some sections (Figure 1B). The
pattern of staining in borderline ovarian tumours was similar to
benign tumours exhibiting 450% of epithelial staining. Both
cytoplasmic and nuclear staining was observed, but the distribu-
tion of staining was predominantly nuclear (Figure 1C). Stromal
nuclei and cytoplasm were also stained positive. Low-to-moderate
extent of staining was observed in both the epithelium and stroma
of benign and borderline tumours.
Grades 1, 2 and 3 tumours Grade 1 ovarian tumours exhibited
less staining than their benign and borderline counterparts (Figure
2A and B). Four out of nine tumours exhibited o50% epithelial
staining, and in some tumours staining as little as 15% was
observed (Table 1). Staining of the epithelial cells was mostly
nuclear but some cytoplasmic staining was also evident. Stromal
staining was also reduced with four samples demonstrating o10%
staining (Table 1). Grades 2 and 3 tumours also showed less
PPARb and PDK1 in ovarian cancer
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sstaining than benign and borderline tumours (Figure 2C and D).
Staining was mostly confined to epithelial cells with minimum
stromal staining. Staining was predominantly nuclear, although
some degree of cytoplasmic staining was also evident. Nuclear
staining of infiltrating macrophages was also evident in some
sections. The staining intensity in both the epithelium and stroma
of grades 1, 2 and 3 tumours was weak.
Immunohistochemical expression of PDK1 in ovarian
tissues
Normal ovaries and benign tumours No staining of PDK1 was
evident in 9 out of 10 normal ovaries used in the study (Table 2,
Figure 3A). Very weak cytoplasmic staining of the epithelium was
present in one ovary. Four out of 10 benign tumours showed
negative PDK1 staining (Table 2, Figure 3B), whereas weak
cytoplasmic staining was evident in 5 out of 10 benign tumours.
Only one serous benign tumour demonstrated moderate staining
for PDK1, and it was mostly confined to the inclusion cysts present
in the section (Figure 3C). Stromal staining was not evident in
either normal ovaries or in benign tumours. Staining of the blood
vessels was evident in the sections that contained them.
Borderline and grades 1–3 tumours Ten pre-malignant border-
line ovarian tumours revealed low (n¼5), moderate (n¼2) and
high (n¼3) PDK1 expression (Table 2 and Figure 3D). Most of the
tumours displayed diffuse cytoplasmic staining with few sites
displaying membrane staining confined to the epithelium. High
extent of staining was observed in serous ovarian tumours. In
AB
C
E
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Figure 1 Expression of PPARb in normal ovaries, benign and borderline tumours. Archival ovarian tissues were stained by the immunoperoxidase
method as discussed in the Materials and methods section. (A) Normal ovary, long arrow showing continuous expression of PPARb in the epithelium,
whereas the short arrow illustrates PPARb expression in the stroma. (B) Benign serous ovarian tumour, long arrow displays nuclear epithelial staining while
short arrows indicate epithelial staining of the inclusion cysts; (C) benign mucinous tumour, arrow indicates nuclear epithelial staining. (D) Borderline, serous
and (E) borderline mucinuous tumours. Long arrows in each case indicate positive epithelial PPARb staining, whereas short arrow illustrates positive staining
of the stroma.
Table 1 The extent of PPARb expression in normal ovaries and ovarian
tumours
Histology
Total number
of tissues
Extent of staining
in the epithelium
(number of tissues)
Extent of staining
in the stroma
(number of tissues)
Normal 10 1(1), 2(1), 3 (4), 4(4) 1(1), 2(5), 3(4)
Benign 10 1(3), 2(1), 3(1), 4(2), 5(3) 2(2), 3(3), 4(2), 5(3)
Borderline 10 3(1), 4(5), 5(4) 3(5), 4(4), 5(1)
Grade 1 9 1(3), 2(1), 3(5) 0(4), 1(3), 2(2)
Grade 2 10 0 (3), 1 (2), 3 (4), 4(1) 0(5), 1(3), 2(2)
Grade 3 10 0 (1), 1 (6), 2 (3) 0(5), 1(3), 2(2)
Total 59
PPARb, peroxisome proliferator-activated receptor b. The extent of PPARb
expression was scored as 0 (p10%), 1 (X11–25%), 2 (X26–50%), 3 (X51–
75%), 4(X76–90%) and 5 (X91–100%) immunoreactivity. Values in the
parentheses indicate number of tissues in each category.
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ssome sections, weak staining of the reactive stroma adjacent to the
epithelium was also evident (Figure 3D). Weak staining of the
blood vessels was also present in some sections (Figure 3D).
Nine grade 1 tumours were available for examination. Two of
the grade 1 tumours displayed week staining, whereas moderate
staining was evident in five grade 1 tumours with high extent of
staining in two endometrioid grade 1 tumours. In case of grade 1
tumours, both cytoplasmic and membrane staining were displayed
(Figure 4A and B), with the degree of membrane staining more
prevalent than in borderline tumours. Staining was mostly
confined to the epithelium, and some degree of the staining of
the reactive stroma was evident in the sections that contained them
(Figure 4). Twenty-two grades 2 and 3 ovarian tumours were
examined for PDK1 expression. Out of these, only two grade 2
tumours displayed weak staining, whereas six displayed moderate
staining and the rest (n¼14) displayed high extent of staining. The
staining pattern of grades 2 and 3 tumours was similar to that of
grade 1 tumours (Figure 4C–E), with the occurrence of more
membrane staining of the epithelial cells compared to the diffuse
cytoplasmic staining. The extent of staining ranged from the
majority of tumour cells to scattered positive cells in some
sections. Multiple nests of cells displayed diffuse cytoplasmic
staining that ranged in intensity. In some sections, the intercellular
membranes were highlighted in some areas, whereas in others
there was more involvement of the cytoplasm.
None of the tissues showed any positive staining with the
control IgG antibodies (Figure 5).
Statistical analysis
PPARb: The extent of staining in the epithelium and stroma was
significantly different within normal and different histological
grades of cancer (w
2¼59.25, d.f.¼25, Po0.001; w
2¼64.48,
d.f.¼25, Po0.001). The extent of epithelial and stromal staining
between normal ovaries and grades 1, 2 and 3 tumours was also
significantly different (w
2¼11.28, d.f.¼4, Po0.05; w
2¼16.15,
d.f.¼4, Po0.005). There was no significant difference in the
extent of epithelial staining between normal vs benign/borderline
groups. However, significance was observed with respect to
stromal staining (w
2¼11.58, d.f.¼4, Po0.05) between normal
and benign/borderline tumours. Within the tumours, the extent of
staining in the epithelium and stroma was significantly different in
benign and borderline tumours compared with grades 1, 2 and 3
tumours (w
2¼25.53, d.f.¼5, Po0.001; w
2¼42.80, d.f.¼5,
Po0.001).
PDK1: The expression of immunoreactive PDK1 was present in
only 10% of normal ovaries and 60% of benign ovarian tumours.
The extent of staining in the epithelium was significantly different
within normal and different histological grades of cancer
(w
2¼71.32, d.f.¼25, Po0.001). Within the tumours, the extent
of staining in the epithelium was significantly different between
benign/borderline vs grades 1, 2 and 3 groups (w
2¼22.45, d.f.¼5,
Po0.001); however, no significant difference was observed
between benign and borderline tumours or grades 1, 2 and 3
tumours.
DISCUSSION
We have recently demonstrated that the cytoplasmic and nuclear
expression of PPARg increases progressively with the progression
AB
CD
Figure 2 Expression of PPARb in grades 1, 2 and 3 ovarian tumours. (A) Grade 1 endometrioid; (B) grade 1 mucinuous; (C) grade 2 endometrioid and
(D) grade 3 serous tumours. Arrows in each tumour illustrate positive nuclear PPARb staining of the scattered epithelium.
Table 2 The extent of PDK1 expression in normal ovaries and ovarian
tumours
Histology
Total number
of tissues
Extent of staining
in the epithelium
Normal 10 0 (9), 1 (1)
Benign 10 0 (4), 1 (3), 2 (2), 4 (1)
Borderline 10 1 (2), 2 (3), 3 (2), 4 (3)
Grade 1 9 2 (2), 3 (5), 4 (2)
Grade 2 11 2 (2), 3 (4), 4 (4), 5 (1)
Grade 3 11 3 (2), 4 (7), 5 (2)
Total 61
The extent of PDK1 expression was scored as 0 (p10%), 1 (X11–25%), 2 (X26–
50%), 3 (X51–75%), 4(X76–90%) and 5 (X91–100%) immunoreactivity. Values
in the parentheses indicate number of tissues in each category.
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sof ovarian carcinoma (Zhang et al, 2005). We have also
demonstrated enhanced expression of ILK, a putative target gene
of PPARb, in high-grade ovarian tumours (Ahmed et al, 2003) and
the presence of cell-free irILK in the serum and ascites of ovarian
cancer patients (Ahmed et al, 2004). On the basis of these
observations, we hypothesised that the expression of PPARb and
its downstream target PDK1 will also change with the progression
of ovarian carcinoma. In this study, we report the differential
expression of PPARb and PDK1 in normal human ovaries and
ovarian tumours of different histological grades and subtypes.
Normal ovarian tissues expressed PPARb. The expression was
moderate, predominantly nuclear and localised to both the
epithelium and stroma. Moderate–to-strong expression of PPARb
was observed in benign and borderline tumours with the staining
being predominantly nuclear and localised to the epithelium and
stroma. In some benign tumours, staining of inclusion cysts was
also evident (Figure 1B). In grades 1, 2 and 3 tumours, scattered
staining of the epithelial cells within the stroma was observed
(Figure 2A–D). Stromal staining was less evident, and in some
tumours o10% of the stromal cells were stained. The extent of
staining ranged from negative to moderate with few high-grade
tumours demonstrating no epithelial or stromal staining. In some
high-grade tumours, infiltrating macrophages often demonstrated
moderate staining, consistent with the relatively high expression of
PPARb in macrophages (Feige et al, 2006). These results suggest
that PPARb is expressed in the epithelium and stroma of normal
ovaries, benign, borderline and low- to high-grade ovarian
tumours, but compared to benign and borderline tumours, there
is a declining pattern of expression in high-grade ovarian tumours.
The expression of PPARb has been demonstrated previously in the
theca and stromal component of normal ovaries (Froment et al,
2006). Considering that the expression and activation of PPARb is
usually triggered by inflammation (Tan et al, 2001) and that
normal ovaries undergo inflammation-mediated responses even
immediately after menopause (due to high levels of gonadotro-
phins), the persistent expression of PPARb in the epithelial and
stromal component of normal ovaries of the control group used in
the study is not surprising. A recent study, however, has
demonstrated the expression of PPARb in mouse models of
ovarian tumours as well as the that PPARb mRNA and protein to
be expressed in tumours generated in vivo by mouse ovarian
cancer cell lines, whereas low-to-undetectable levels of PPARb
were expressed in normal mouse ovaries and non-tumourous
ovarian samples (Daikoku et al, 2007). The lack of PPARb
expression in normal mouse ovaries and non-tumorous ovarian
samples may be attributed to differences in the techniques (in situ
hybridisation and Western blot compared to immunohistochem-
istry) used in both studies or may be the result of a cell type-
specific response generated in immunocompromised mice by
oncogene (Kras, cmyc, RCAS, Akt, and so on) carrying virus-
transfected mouse ovarian cell lines (Daikoku et al, 2007).
The relatively high expression of PPARb in differentiated benign
and borderline ovarian tumours compared to high-grade tumours
may implicate its known role in differentiation described
previously in keratinocytes, colonocytes and breast cancer cells
(Di-Poi et al, 2005; Aung et al, 2006). Besides keratinocytes,
PPARb has also been shown to regulate the differentiation of
primary macrophages or a monocyte/macrophage cell line (Vosper
et al, 2001). The activation of PPARb using a selective agonist
promotes oligodendrocyte differentiation in a mouse cell culture
model (Saluja et al, 2001) consistent with the myelination defect of
the corpus callosum in PPARb null mice (Peters et al, 2000).
Peroxisome proliferator-activated receptor b also contributes to
adipose tissue differentiation as demonstrated by the decrease in
fat mass in PPARb null mice (Peters et al, 2000; Barak et al, 2002).
In cancers, ligand activation of PPARb has been shown to
attenuate colon carcinogenesis (Harman et al, 2004; Marin et al,
2006), and decreased PPARb expression has been displayed by
microarray analysis in high-grade tumour samples compared to
control tissues, suggesting that decreased expression of PPARb
may be linked to an increase in the loss of differentiation required
for the progression of colon malignancies (Notterman et al, 2001).
AB
CD
Figure 3 Expression of PDK1 in normal ovaries, benign and borderline ovarian tumours. Archival ovarian tissues were stained by the methods discussed in
the Materials and methods section. (A) Normal ovary, no staining of the epithelium was evident, but very weak staining of the blood vessel is indicated by a
short arrow. (B) Benign mucinous ovarian tumour lacking PDK1 expression in the epithelium; (C) benign serous ovarian tumour illustrating strong PDK1
staining of the inclusion cysts (long arrow) and blood vessels (short arrow). (D) Borderline mucinous ovarian tumour, long arrow displays positive PDK1
staining of the epithelium, whereas short arrow illustrates weak staining of the blood vessels.
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expression of PPARb in high-grade ovarian carcinomas may
implicate the inability of the tumours to maintain differentiation
with the progression of the malignancy.
The involvement of PPARb in colorectal cancer is complex and
seems to be regulated by pathways other than those controlling
cellular differentiation. A recent report showed that the expression
and activation of PPARb is increased in rat intestinal cells by the
overexpression of activated Kras oncogene (Shao et al, 2002). In
another colorectal cancer cell xenograft model, the absence of
PPARb decreased tumorigenicity, indicating that the expression of
PPARb may be involved with colon tumorigenesis (Park et al,
2001a). In contrast, APC
MinPPARb null mouse showed no
requirement for PPARb for polyp formation (Barak et al, 2002),
indicating that the increased activity of PPARb on an APC-null
background might be one of the factors supporting colorectal
tumorigenesis (Michalik et al, 2004). Hence, the status of PPARb
expression in colorectal cancer is controversial and whether it is
regulated by the APC or the Kras oncogene yet remains to be
determined.
Some recent studies have shown PPARb as a potent inhibitor of
PPARa- and PPARg-activated transcription (Shi et al, 2002). The
induced expression of PPARb in 3T3-PPARg adipocytes inhibited
PPARg-induced gene expression and adipogenesis (Bastie et al,
1999). The increased expression of PPARb in hepatic stellate cells
induced increased proliferation and fibrogenesis with concomitant
decreased expression of PPARg (Hellemans et al, 2003), suggesting
that PPARb and PPARg may be inversely regulated. These studies
are consistent with our previous study where we have reported
enhanced expression of PPARg in high-grade ovarian tumours
compared with benign and borderline ovarian tumours (Zhang
et al, 2005). Hence, a balance of PPARb and PPARg expression and
activation may be needed to regulate ovarian tumour differentia-
tion and metastases.
In contrast to PPARb expression, PDK1 expression was absent
in 90% of normal ovaries, and low expression of PDK1 was evident
in only 1 out of 10 normal ovaries. In the case of benign ovarian
tumours, o50% were negative for PDK1 expression, whereas the
rest displayed low-to-moderate PDK1 expression confined to the
cytoplasm and membranes of the epithelium. Nearly 50% of
borderline ovarian tumours displayed low expression of PDK1 and
the other 50% demonstrated moderate-to-high expression. There
was a gradual increase in the expression of PDK1 with increasing
grades of ovarian tumours, with the bulk of the high-grade
tumours demonstrating high expression of cytoplasmic and
membrane-bound PDK1. The apparent increase in PDK1 expres-
sion in high-grade ovarian carcinomas is consistent with our
previously reported parallel increase in ILK expression with
increasing grade of ovarian carcinomas (Ahmed et al, 2003). A
similar trend of heightened expression of both ILK and PDK1 in
high-grade ovarian tumours may suggest enhanced activation of
upstream PI-3 kinase and/or PPARb cascades required for tumour
AB
CD
E
Figure 4 Expression of PDK1 in grades 1, 2 and 3 ovarian tumours. (A) Grade 1 mucinuous and (B) grade 1 endometrioid tumours displaying strong
PDK1 staining. (C) Grade 2 serous tumour, long arrow indicates strong epithelial staining and short arrow exhibits staining of the reactive stroma. (D) Grade
3 serous tumour displaying scattered epithelial tumour cells positively stained for PDK1. (E) Grade 3 serous ovarian tumour strongly positive for PDK1
staining.
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Met receptor, EGFR, and so on) and their downstream signalling
such as PI-3 kinase has been reported in high-grade ovarian
tumours (Stadlmann et al, 2006; Sawada et al, 2007). As the
expression of PPARb does not get elevated in high-grade ovarian
tumours, it can be suggested that sustained activation of the PI-3
kinase pathway either due to aberrant activation of growth factor
receptors or loss of PTEN function may be required to maintain
elevated expression and activation of ILK, PDK1 and the down-
stream Akt and Wnt pathways in advanced ovarian tumours.
The transforming ability of PDK1 in vitro and in vivo is
mediated by PKCa and is linked to c-myc function and the
expression of caveolin-1, an integral protein component of
caveolae known for its role as a tumour suppressor (Xie et al,
2003). The forced expression of PDK1 and PKCa in mammary
epithelial cells results in the upregulation of c-Myc with correlated
downregulation of caveolin-1 expression and gain of transforma-
tion (Xie et al, 2003). Overexpression and amplification of c-myc
gene copy number have been reported in ovarian tumours
(Dimova et al, 2006), and the inhibition or depletion of PKCa
activity has been shown to inhibit drug resistance (Masanek et al,
2002) or sensitise ovarian cancer cells to platinum drugs (Isonishi
et al, 2000). Moreover, caveolin-1 expression, which has been
demonstrated in normal and benign ovarian tumours, has been
shown to recede in high-grade ovarian carcinomas, and forced
expression of caveolin-1 in ovarian cancer cells resulted in loss of
cell survival, consistent with the tumour-suppressing role of
caveolin-1 described for other cancers (Wiechen et al, 2001).
Taken together, these observations suggest a correlative link
between PDK1, c-myc, PKCa and caveolin-1 in ovarian tumours
and are consistent with those observed in mammary epithelial cell
models (Xie et al, 2003, 2006).
In conclusion, a better understanding of PPARb function as well
as its activation and repression in in vitro and in vivo models of
ovarian cancer is needed to ascertain its role as a potential
therapeutic target. On the other hand, the lack of PDK1 expression
in normal ovaries, its weak expression in benign tumours and its
elevated expression in pre-malignant and low- to high-grade
ovarian carcinomas provide compelling evidence of its oncogeneic
role in ovarian cancer progression. Hence, like other cancers,
PDK1 may be a preferred molecular target for sensitising ovarian
cancer cells to chemotherapeutic agents (Feldman et al, 2005).
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